

## **Antibiotics-Anti-Infectives Workgroup**

Following review of the drugs listed in these classes on the Preferred Drug List, the workgroup recommends to the Michigan Pharmacy and Therapeutics Committee the following:

### **Antifungals-Onychomycosis**

No change to the listings as currently presented

### **Anti-fungals-Oral**

No change to the current listings

### **Antivirals-Herpes**

No change to the current listings

### **Antivirals-Influenza**

Return prior authorization to Tamiflu® and Relenza®

### **Cephalosporin-First Generation**

No change to the current listings

### **Cephalosporin-Second Generation**

No change to the current listings

### **Cephalosporin-Third Generation**

No change to the current listings

### **Hepatitis C**

Add ribavirin as available without prior authorization

Require prior authorization on brand name Copegus®

### **Ketolides**

Require prior authorization on Ketek® to review for awareness of toxicity

### **Macrolides**

Add azithromycin without prior authorization

Add clarithromycin without prior authorization

Require prior authorization on Zithromax®, Biaxin®, BiaxinXL®

### **Quinolones**

Require prior authorization for CiproXR®